A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB410 for Injection in Subjects with Advanced Solid Tumors
Latest Information Update: 28 Jan 2025
At a glance
- Drugs SKB-410 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 27 Jun 2024 Status changed from not yet recruiting to recruiting.
- 23 Jun 2023 New trial record